BRIDGenomics


Consulting firm focused on genomics strategy, assay development, and commercialization support. Offers technical and regulatory guidance for next-generation sequencing (NGS) and molecular diagnostics, including assay design, validation, workflow automation, and alignment with regulatory oversight for laboratory-developed tests (LDTs).

Industries

biopharma
biotechnology
genetics
life-science
professional-services

Nr. of Employees

small (1-50)

BRIDGenomics

Friendsville, Tennessee, United States, North America


Services

Advisory services to support partnering, outsourcing strategy, and connections between diagnostic manufacturers, labs, and pharma.

Commercial and market-strategy services for genomics-based products and services.

Technical and strategic services related to NGS assay development and implementation.

Support for development and prioritization of assay and product pipelines in genomics.

Guidance on developing laboratory-developed tests and aligning processes with FDA oversight where applicable.

Evaluation of new genomic and sequencing technologies for potential clinical and commercial application.

Expertise Areas

  • Next-generation sequencing assay development
  • Molecular diagnostic assay design
  • Assay validation and clinical performance testing
  • LDT regulatory compliance and FDA alignment
  • Show More (4)

Key Technologies

  • Next-generation sequencing (NGS)
  • Advanced sequencing technologies
  • Automated assay systems
  • Sequencing-based diagnostics
  • Show More (2)

News & Updates

Participation or listing for Next Generation Dx Summit; includes related podcast and agenda links.

Event listing and related podcast reference.

Podcast referenced on the events page related to next-generation diagnostics.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.